AKT1 and primary cutaneous T-cell non-Hodgkin lymphoma: miR-122 is thus an amplifier of the antiapoptotic Akt/p53 circuit and it is conceivable that a pharmacological intervention in this pathway may provide basis for novel therapies for CTCL.